Cargando…
A Refractory Case of CDKN2A/B Loss Metastatic Intrahepatic Cholangiocarcinoma Achieving a Partial Response After First-Line Treatment with Palbociclib
Intrahepatic cholangiocarcinoma (ICC) is a highly aggressive and malignant subtype of biliary duct tumors. The poor prognosis of advanced ICC brings great challenges to clinical treatment, and chemotherapy-based therapy remains the standard first-line regimen. In recent years, the development of cli...
Autores principales: | Fan, Weiming, Wang, Chuan, Zhong, Xuefeng, Zheng, Yating, Chen, Tingting, Huang, Mengli, Su, Shuying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869796/ https://www.ncbi.nlm.nih.gov/pubmed/36698435 http://dx.doi.org/10.2147/OTT.S390458 |
Ejemplares similares
-
An unresectable and metastatic intrahepatic cholangiocarcinoma with EML4-ALK rearrangement achieving partial response after first-line treatment with ensartinib: a case report
por: Huang, Senmiao, et al.
Publicado: (2023) -
HMGA1 augments palbociclib efficacy via PI3K/mTOR signaling in intrahepatic cholangiocarcinoma
por: Li, Zhipeng, et al.
Publicado: (2023) -
Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss
por: Frisone, Daniele, et al.
Publicado: (2019) -
Sustained Complete Response to Palbociclib in a Refractory Pediatric Sarcoma With BCOR-CCNB3 Fusion and Germline CDKN2B Variant
por: Tramontana, Timothy F., et al.
Publicado: (2020) -
Partial treatment response to capmatinib in MET-amplified metastatic intrahepatic cholangiocarcinoma: case report & review of literature
por: Lefler, Daniel S, et al.
Publicado: (2022)